Bill
HR 5316
The Drug Shortage Compounding Patient Access Act of 2025 improves access to compounded medications by streamlining processes and incentivizing pharmacies to address shortages.
The Drug Shortage Compounding Patient Access Act of 2025 aims to address the growing issue of drug shortages in the United States, particularly focusing on the compounding of medications. The bill seeks to enhance patient access to necessary medications by streamlining the compounding process and ensuring that patients can receive timely and effective treatments.
The bill includes several important provisions designed to improve the compounding of drugs and mitigate shortages:
Regulatory Framework: Establishes a clearer regulatory framework for compounding pharmacies, allowing them to produce medications in response to shortages more efficiently.
Incentives for Compounding: Provides incentives for compounding pharmacies to produce drugs that are in short supply, potentially including financial support or expedited approval processes.
Reporting Requirements: Introduces new reporting requirements for manufacturers and pharmacies regarding drug shortages, ensuring that information is shared promptly with healthcare providers and patients.
Collaboration with FDA: Encourages collaboration between compounding pharmacies and the Food and Drug Administration (FDA) to identify and address shortages proactively.
The primary stakeholders affected by this legislation include:
Patients: Individuals who rely on compounded medications for their health needs will benefit from improved access to these drugs during shortages.
Healthcare Providers: Doctors and pharmacists will have better access to information regarding drug availability, allowing them to make informed decisions for patient care.
Compounding Pharmacies: These businesses will have clearer guidelines and potential support to help them meet patient needs during shortages.
Drug Manufacturers: Manufacturers will be required to adhere to new reporting standards, impacting their operations and supply chain management.
Introduced Date: The bill was introduced in the House on September 11, 2025.
Committee Referral: Following its introduction, HR 5316 was referred to the House Committee on Energy and Commerce for further consideration.
The Drug Shortage Compounding Patient Access Act of 2025 represents a legislative effort to tackle the critical issue of drug shortages by enhancing the compounding process and improving patient access to essential medications. As the bill progresses through the legislative process, it will be important to monitor its developments and potential impacts on the healthcare system.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
